Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
207 Leser
Artikel bewerten:
(1)

Aescuvest Capital Partners (ACP) Fund Empowers Visionary Healthtech Innovators for High Returns

Finanznachrichten News

MUNICH, Jan. 16, 2025 /PRNewswire/ -- Aescuvest Capital Partners (ACP) is at the forefront of Healthtech investing, leveraging its deep expertise in European healthcare innovation to make a global impact. With a focus on companies nearing pivotal MDR and FDA approvals, ACP is not just an investor but a catalyst for transformative change in healthcare.

Dr. Patrick Pfeffer, CEO - Aescuvest

Over the past four years, ACP has honed a patient-centred investment strategy, targeting ventures that promise significant financial returns and the potential to redefine healthcare.

"Our mission extends beyond financial gains; we aim to support companies that will transform healthcare delivery," said Christoph Bartoschek, ACP's Investment Principal. With a strong background in healthcare finance and strategic investments, Bartoschek utilizes ACP's extensive network and regulatory insights to expedite approval processes, ensuring portfolio companies achieve critical milestones efficiently. "Our strategic partnerships and regulatory expertise give us a competitive edge in predicting approval timelines and driving success."

ACP's network has reach beyond Europe, into the US, Middle East and other key markets. Aescuvest's diverse portfolio includes cutting-edge diagnostics and innovative solutions addressing diseases affecting over 80% of the global population, underscoring their commitment to impactful health innovation.

Dr. Patrick Pfeffer, Managing Partner at ACP, is a visionary leader driving the firm's mission to invest in financially sound companies that are also agents of global health change. With anchor investors like the von Siemens family, and other well-established German industrial partners providing industry insights and networks, ACP is strategically positioned to partner with major healthcare entities, viewing their portfolio companies as future acquisition targets.

"We are building a legacy that marries financial success with societal impact," said Dr. Pfeffer. ACP dedicates 5% of its earnings to Nurse Heroes, a global initiative tackling the critical nurse shortage, and supports innovators like their portfolio companies Neteera Technologies and Lillian Care, who are developing technology to enhance the caregiving workforce.

In a rapidly evolving regulatory environment, especially concerning AI in healthcare, ACP is poised to navigate and shape the industry's future. This blend of foresight, heritage, and strategic acumen positions Aescuvest Capital Partners not only as an investor but as a visionary leader in the Healthtech sector. ACP are celebrating their launch from 26th - 27th January 2025 at the DxPx Europe Conference in Münich, a conference connecting key leaders from the diagnostics innovation space with investment opportunities - registration for the event is open now.

About Aescuvest

Aescuvest is a healthcare investment company dedicated to funding healthcare technology ventures that make a significant impact. Operating a specialized investment platform, the company offers exclusive access to promising healthcare opportunities and facilitates direct investments through SPV structures. By providing entrepreneurial investments in a thriving market, Aescuvest enables investors to engage in lucrative healthcare investment opportunities.

About Aescuvest Capital Partners (ACP)

Born from the success and expertise of Aescuvest, Aescuvest Capital Partners (ACP) is the latest chapter in advancing healthcare innovation. Built by the visionary partners behind Aescuvest, ACP brings a fresh approach to investment while staying rooted in Aescuvest's proven legacy of backing transformative healthcare technology ventures. With deep industry connections, a track record of success, and a passion for shaping the future of healthtech, ACP is the exciting next step in Aescuvest's mission to empower life-changing innovations.

Media Inquiries:
Riya Gopalakrishnan, riya.gopalakrishnan@redhill.world

Photo - https://mma.prnewswire.com/media/2599335/Aescuvest_Capital_Partners.jpg
Logo - https://mma.prnewswire.com/media/2599336/Aescuvest.jpg

Aescuvest

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/aescuvest-capital-partners-acp-fund-empowers-visionary-healthtech-innovators-for-high-returns-302353123.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.